Structure Therapeutics' oral GLP‑1 pill cuts 16% weight
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Structure Therapeutics announced that its Phase 2 trial of the oral GLP‑1 pill aleniglipron produced a 16% average weight loss versus placebo after 44 weeks.
- Eli Lilly's oral GLP‑1 candidate orforglipron previously showed about 11% weight loss in a 72‑week study and is slated for U.S. regulatory approval imminently.
- Novo Nordisk entered the oral GLP‑1 market by launching an oral version of Wegovy late last year.
- Structure Therapeutics could use the Phase 2 data to challenge Lilly and Novo in the oral GLP‑1 obesity drug race.
Why it matters: Structure Therapeutics gains a credible foothold in the oral GLP‑1 market, potentially eroding Lilly’s and Novo’s first‑mover advantage while offering patients a non‑injectable obesity treatment. The 16% weight loss result suggests oral agents can match injectable efficacy, prompting insurers and clinicians to reassess treatment strategies.
Ask SkimNews
